To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
Public ClinicalTrials.gov record NCT03331523. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Taclonex® Topical Suspension (LEO Pharma Inc.) in the Treatment of Scalp Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd to that of the marketed product Taclonex® topical suspension of Leo Pharma Inc. in the treatment of scalp psoriasis.
Study identification
- NCT ID
- NCT03331523
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 643 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2017 (Actual)
- Primary completion
- Oct 25, 2018 (Actual)
- Completion
- Oct 25, 2018 (Actual)
- Last update posted
- Dec 21, 2018
2017 – 2018
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site 24 | Encinitas | California | 92024 | — |
| Investigational Site 3 | Fremont | California | 94538 | — |
| Investigational Site 13 | San Diego | California | 92108 | — |
| Investigational Site 20 | San Diego | California | 92123 | — |
| Investigational Site 32 | Santa Monica | California | 90404 | — |
| Investigational Site 14 | Denver | Colorado | 80220 | — |
| Investigational Site 1 | Miami | Florida | 33144 | — |
| Investigational Site 30 | Miami | Florida | 33175 | — |
| Investigational Site 7 | Miramar | Florida | 33027 | — |
| Investigational Site 22 | Tampa | Florida | 33609 | — |
| Investigational Site 15 | New Albany | Indiana | 47150 | — |
| Investigational Site 10 | South Bend | Indiana | 46617 | — |
| Investigational Site 21 | Louisville | Kentucky | 40241 | — |
| Investigational Site 6 | Ann Arbor | Michigan | 48103 | — |
| Investigational Site 12 | Fridley | Minnesota | 55432 | — |
| Investigational Site 26 | Saint Joseph | Missouri | 64506 | — |
| Investigational Site 17 | Henderson | Nevada | 89052 | — |
| Investigational Site 25 | Las Vegas | Nevada | 89128 | — |
| Investigational Site 29 | Forest Hills | New York | 11375 | — |
| Investigational Site 28 | Rochester | New York | 14623 | — |
| Investigational Site 4 | High Point | North Carolina | 27262 | — |
| Investigational Site 18 | Fountain Inn | South Carolina | 29644 | — |
| Investigational Site 27 | Mt. Pleasant | South Carolina | 29464 | — |
| Investigational Site 9 | Knoxville | Tennessee | 37922 | — |
| Investigational Site 8 | Nashville | Tennessee | 37215 | — |
| Investigational Site 5 | Austin | Texas | 78759 | — |
| Investigational Site 11 | College Station | Texas | 77845 | — |
| Investigational Site 16 | San Antonio | Texas | 78213 | — |
| Investigational Site 19 | San Antonio | Texas | 78249 | — |
| Investigational Site 31 | Norfolk | Virginia | 23507 | — |
| Investigational Site 23 | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03331523, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2018 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03331523 live on ClinicalTrials.gov.